… , epigenetics and tumor microenviroment, the mode of diagnosis and treatment would also
be … and molecular mechanism of gastroenteropancreatic neuroendocrine neoplasms will be …

… Recently, reinfusion of autologous umbilical cord blood or immune cells from cord blood
has been proposed as a novel therapy for T1DM, with the advantages of no risk to the donors, …

… and no consensus on treatment strategy.(Purpose)We study the treatment strategy of the …
the treatment of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs)in Japan. The …

… autoimmune disease mediated by autoimmune attack against pancreatic β-cells. It has been
… What this study adds: This study provides a novel molecular explanation for the sustained …

… The most common clinical tumor marker for pancreatic cancer is carbohydrate antigen (CA)
19-9, with a median sensitivity of 79% and median specificity of 82%.13 However, CA 19-9 …

… neuroendocrine neoplasms with high proliferative activity, general adenocarcinomas with
neuroendocrine differentiation and molecular … great value for diagnosis and treatment of NENs. …

… These analogs, alone or in combination with other agents (also as preoperative treatment), …
neuroendocrine tumors, and in gastrointestinal indications, ie complications after pancreatic …

… novel therapeutic agents based on studies of GLP-1. It is worth mentioning that brain GLP-1
signaling controls satiety, and the body mass lowering effect of GLP-1 based drugs are also …

… Endocrine and exocrine pancreatic insufficiency, brittle glycemic control, and insulin-requiring,
ketosis-resistant diabetes are the novel … therapeutic strategies in future studies on FCPD. …

… ) as a novel protein expressed in pancreatic β-cells. As a member of the “CCN” ( C ysteine-rich
angiogenic inducer 61 [Cyr61], C onnective tissue growth factor [CTGF in humans], and N …